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Abstract
 
The recently described junctional adhesion molecules (JAMs) in man and mice are involved in
homotypic and heterotypic intercellular interactions. Here, a third member of this family, hu-
man JAM-3, was identified and described as a novel counterreceptor on platelets for the leuko-
cyte 
 
 
 
2-integrin Mac-1 (
 
 
 
M
 
 
 
2, CD11b/CD18). With the help of two monoclonal antibodies,
Gi11 and Gi13, against a 43-kD surface glycoprotein on human platelets, a full-length cDNA
encoding JAM-3 was identified. JAM-3 is a type I transmembrane glycoprotein containing two
Ig-like domains. Although JAM-3 did not undergo homophilic interactions, myelo-monocytic
cells adhered to immobilized JAM-3 or to JAM-3–transfected cells. This heterophilic interaction
was specifically attributed to a direct interaction of JAM-3 with the 
 
 
 
2-integrin Mac-1 and to a
lower extent with p150.95 (
 
 
 
X
 
 
 
2, CD11c/CD18) but not with LFA-1 (
 
 
 
L
 
 
 
2, CD11a/CD18)
or with 
 
 
 
1-integrins. These results were corroborated by analysis of K562 erythroleukemic cells
transfected with different heterodimeric 
 
 
 
2-integrins and by using purified proteins. Moreover,
purified JAM-3 or antibodies against JAM-3 blocked the platelet-neutrophil interaction, indicat-
ing that platelet JAM-3 serves as a counterreceptor for Mac-1 mediating leukocyte–platelet in-
teractions. JAM-3 thereby provides a novel molecular target for antagonizing interactions be-
tween vascular cells that promote inflammatory vascular pathologies such as in atherothrombosis.
Key words: monoclonal antibody • adhesion molecule • integrins • neutrophils • athero- 
thrombosis
 
Introduction
 
Multicellular interactions between leukocytes and the vessel
wall play a pivotal role in inflammatory processes or vascu-
lar remodeling. Leukocyte recruitment to vascular endo-
thelium requires multistep adhesive and signaling events in-
cluding selectin-mediated rolling, leukocyte activation, and
integrin-mediated firm adhesion and diapedesis (1). On the
leukocytes, members of the 
 
 
 
2-integrin family, LFA-1
(
 
 
 
L
 
 
 
2, CD11a/CD18), Mac-1 (
 
 
 
M
 
 
 
2, CD11b/CD18),
and p150.95 (
 
 
 
X
 
 
 
2, CD11c/CD18), as well as 
 
 
 
1-inte-
grins interact with endothelial counterligands such as inter-
cellular adhesion molecule 1 (ICAM-1)
 
*
 
 (2), surface-asso-
ciated fibrinogen (3), or vascular cell adhesion molecule
(VCAM)-1, to mediate the described paracellular interac-
tions. At sites of vascular injury, where the endothelial cell
lining has been denuded, leukocyte infiltration can occur
through interactions with deposited platelets and fibrin (4).
In vivo studies indeed demonstrated colocalization of both
cell types within atherosclerotic and postangioplasty reste-
notic lesions, or in areas of ischemia-reperfusion injury (5,
6). Reminiscent of the leukocyte–endothelium interac-
tions, a sequential adhesion process including leukocyte
attachment to and transmigration across surface-adherent
platelets, has been proposed: Platelet-P-selectin–mediated
initial tethering and rolling of leukocytes through their
P-selectin glycoprotein ligand-1 (PSGL-1) is followed by
Mac-1–dependent firm adhesion and transplatelet migra-
tion (7). Recent data indicated glycoprotein (GP) Ib
 
 
 
 on
platelets as a potential counterreceptor for Mac-1 (8). Fur-
thermore, ICAM-2 and 
 
 
 
IIb
 
 
 
3-associated fibrinogen have
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also been proposed to mediate Mac-1–dependent platelet–
leukocyte interactions (9, 10); however, the exact contri-
bution of each system remains to be elucidated.
Recently, new members of the Ig-superfamily named
junctional adhesion molecules (JAMs), which mediate cell-
to-cell adhesion have been identified on several blood cell
populations. JAM-1 is a transmembrane protein which pos-
sesses two V-type immunoglobulin domains and is found
on endothelial and epithelial cells at sites of cell–cell con-
tacts in particular within tight junctions (11). JAM-1 was
shown to participate in monocyte transmigration across en-
dothelial cells, and blocking mAbs against JAM-1 were able
to inhibit monocyte infiltration and attenuate cytokine-
induced meningitis in mice (12–14). Platelet JAM-1 might
also be involved in primary hemostasis (15–17), as cross-
linking of JAM-1 with Fc
 
 
 
RII resulted in platelet aggrega-
tion. Interestingly, human platelet antibodies against JAM-1
were reported in patients with thrombocytopenia (16).
Human JAM-1 is also constitutively expressed on circulat-
ing monocytes, neutrophils, erythrocytes, and lymphocyte
subsets (18–20). Finally, JAM-1 has been described as a re-
ceptor for reovirus (21). In contrast, JAM-2 (also referred
to as VE-JAM) is prominently expressed at intercellular
boundaries of the endothelium, particularly in venules (22).
JAM-2 is also involved in adhesive processes of lympho-
cytes (23).
In this study, we describe the isolation and characteriza-
tion of a new member of the JAM family, namely JAM-3,
expressed on human platelets, and provide evidence that
JAM-3 is a novel counterreceptor for the integrin Mac-1
(CD11b/CD18) thereby playing a critical role for platelet–
leukocyte interactions.
 
Materials and Methods
 
Antibodies and Purified Proteins.
 
The following mAbs were
used in this study: mAb Gi11 and Gi13 were characterized previ-
ously (24); mAb w6/32 against HLA class I molecule (provided
by Dr. S. Ferrone, New York Medical College, New York, NY);
mAb Gi5, Gi9, and Gi21, specific for 
 
 
 
IIb
 
 
 
3, 
 
 
 
2
 
 
 
1 integrins,
and DAF (CD55), respectively, (25); mAb AP1 against GPIb
 
 
 
(provided by Dr. P. Newman, Blood Research Institute, Mil-
waukee, WI), mAb 60.3 against 
 
 
 
2 integrin subunit (CD18)
(provided by Dr. J. Harlan, University of Washington, Seattle,
WA), mAb L15 against LFA-1 (provided by Dr. C. Figdor, Uni-
versity Medical Center, Nijmegen, Netherlands), mAb CBRM1/5
against Mac-1 (provided by Dr. T. Springer, Harvard Medical
School, Boston, MA); mAb LPM19c against Mac-1 (provided by
Dr. A. May, Deutsches Herzzentrum, Munich, Germany); mAb
3.9 against p150.95 (Ancell; reference 26); 
 
 
 
2-integrin stimulat-
ing mAb Kim127 and Kim185 (provided by Dr. M. Robinson,
Celltech, Slough, UK); mAbs K20 against 
 
 
 
1-chain (CD29),
HP2.1 specific for 
 
 
 
4-integrin (CD49d) and 3G8 against CD16
(Immunotech); mAbs against ICAM-1 and fibrinogen (Dako);
mAb MY4 specific for anti-CD14 (Beckman Coulter); blocking
mAb GA6
 
*
 
 against CD62P (P-selectin) and normal mouse IgG
(Becton Dickinson). Polyclonal antibody against JAM-3 was pro-
duced in rabbits using standard procedures. Purified Mac-1, LFA-1,
and ICAM-1 were a gift from Dr. S. Bodary (Genentech, San
Francisco, CA). There was no contamination of the recombinant
 
Mac-1 preparation with JAM-3. Purified glycocalicin was pro-
vided by Dr. K. Clemetson (Theodor Kocher Institute, Bern,
Switzerland) and purified I-domain of Mac-1 was provided by
Dr. D. Tuckwell (School of Biological Sciences, Manchester,
UK). The stable thromboxane A
 
2
 
 mimetic U46619 was a gift Dr.
Stegmeier, Roche (Mannheim, Germany) and fMLP was from
Sigma-Aldrich. Mab Gi11 was labeled with NHS-LC biotin
(Paesel) as recommended by the manufacturer.
 
Isolation of Gi11 Antigen from Human Platelets.
 
Outdated
platelet concentrates were used as source for purification of Gi11
antigen. Washed platelets were centrifuged with 3,700 
 
g
 
 at 4
 
 
 
C
for 45 min, and the pellet was resuspended to 10
 
10
 
 platelets/ml in
lysis buffer (20 mM Tris, 2 mM EDTA, 150 mM NaCl, 2% NP-
40, 2 mM Pefabloc, pH 7.8). After solubilization (at 4
 
 
 
C for 1 h)
cell debris was removed by centrifugation with 17,000 
 
g
 
 at 4
 
 
 
C
for 45 min. From the supernatant the solubilized Gi11 antigen
was isolated by sequential antibody adsorption steps on nonim-
mune mouse IgG, mAb w6/32, and mAb Gi11, coupled to
Sepharose. Affinity columns were washed with 100 ml washing
buffer (0.1 M Tris, 0.1% NP-40, pH 7.8; flow rate 50 ml/h) and
270 ml cell supernatant was applied onto the first column with a
flow rate of 5–10 ml/h. After sequential washing with (a) 50 ml
0.1 M Tris, 0.5 M NaCl, 0.1% NP-40, pH 7.8, (b) 50 ml 1.0 M
Tris, 0.1% NP-40, pH 7.8, and (c) 50 ml 0.1 M Tris, 0.1% NP-
40, pH 8.0, antigens were eluted from the mAb Gi11 affinity col-
umn with 0.05 M diethylamine, 0.1% NP-40, pH 11.5, in 3.0 ml
fractions into tubes containing 1 ml 1M Tris, 0.1% NP-40, pH
6.8. Eluted antigens were identified by silver staining and immu-
noblot. Gi11 antigen containing fractions were pooled, dialyzed
in PBS containing 0.1% NaN
 
3
 
, 0.1% NP-40, and concentrated
using ultrafiltration technique (Centriplus YM 10; Millipore) to
 
 
 
1 ml. The protein concentration of the purified Gi11 antigen
was determined using bicinchoninic assay (BCA; Perbio).
 
Protein and Peptide Analysis.
 
Protein and peptides (20 to 100
pmol) were sequenced by Edman degradation on an Applied Bio-
systems pulsed-liquid-phase sequencer 477A. For analysis of
amino terminal sequences, gels were electroblotted onto polyvi-
nyliden-difluoride (PVDF) membrane. For internal sequences
bands were excised, and the proteins were digested in situ with
trypsin. Peptides were eluted and separated by capillary HPLC,
and individual fractions were selected for sequencing.
 
Immunoprecipitation and Western Blot Analysis.
 
Cells were sur-
face labeled with 5 mM NHS-LC biotin (Paesel), lysed and sub-
jected to immunoprecipitation as described previously (27). Im-
munprecipitates were analyzed on 10% SDS-PAGE under
nonreducing and reducing conditions, transferred onto nitrocel-
lulose, and visualized using peroxidase labeled streptavidin (dilu-
tion 1:3,000) and chemiluminescence substrate (Amersham Bio-
sciences).
Purified Gi11 antigen (0.5 –1 
 
 
 
g) or 25 
 
 
 
l platelet lysate were
run on 10% SDS-PAGE under nonreducing and reducing condi-
tions. Proteins were then transferred onto nitrocellulose mem-
brane and visualized by silver staining or incubated with mAb
Gi11 (2.5 
 
 
 
g/ml). Bound IgG was detected using peroxidase la-
beled rabbit anti mouse IgG (dilution 1:100,000, Dianova) and
chemiluminescence substrate (Amersham Biosciences).
 
Isolation of Platelet mRNA and Rapid Amplifications of 3
 
 
 
 and 5
 
 
 
cDNA Ends-PCR.
 
Total platelet mRNA was isolated as de-
scribed previously (27). Rapid amplifications of 3
 
 
 
 and 5
 
 
 
 cDNA
ends (RACE) was performed using SMART RACE cDNA Am-
plification Kit (CLONTECH Laboratories, Inc.). PCR primers
GSP-1 (5
 
 
 
-
 
783
 
GGGCATCTGTGCATACAGACGTG
 
808
 
-3
 
 
 
) and
GSP-2 (5
 
 
 
-
 
96
 
CAGTGTTTCTGCACGACCCGCCAAGTC
 
71
 
-3
 
 
 
) 
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were constructed based on the nucleotide sequence accessible in
the GenBank (see below) and were numbered according to the
JAM-3 cDNA sequence (see Fig. 2).
 
Generation of JAM-3 Construct.
 
30 
 
 
 
l of platelet mRNA were
heated to 68
 
 
 
C for 10 min and quickly cooled on ice water.
First-strand cDNA was synthesized using 1 
 
 
 
l pd(N)
 
6
 
 primer and
first-strand beads (Amersham Biosciences) according to the man-
ufacturer’s protocol. Aliquots of 20 
 
 
 
l were preheated to 90
 
 
 
C
for 5 min and digested with 2U RNaseH enzyme (GIBCO
BRL) at 37
 
 
 
C. 20 
 
 
 
l cDNA were diluted with 10
 
 
 
 PCR buffer,
and 3 
 
 
 
l (5 
 
 
 
M) GSP-3 (5
 
 
 
-
 
1
 
ATGGCGCTGAGGCGGCCA
 
18
 
-3
 
 
 
),
3 
 
 
 
l (5 
 
 
 
M) GSP-4 (5
 
 
 
-
 
933
 
TCAGATCACAAACGATGAC
 
915
 
-
3
 
 
 
), 8 
 
 
 
l (1.25 mM) dNTP and 2 U Taq Gold polymerase (Perk-
inElmer) were added in a total volume of 50 
 
 
 
l. Amplification
was performed on a DNA thermal cycler 480 (PerkinElmer) for
32 cycles. Each cycle consisted of denaturation at 95
 
 
 
C for 30 s,
annealing at 50
 
 
 
C for 30 s, and extension at 72
 
 
 
C for 60 s. In the
final cycle, the samples were kept at 72
 
 
 
C for 10 min and then
chilled to 4
 
 
 
C. Amplified JAM-3 cDNA was purified using
QIAquick gel extraction kit (QIAGEN) and subcloned into the
T/A cloning site of the plasmid vector pcDNA4His/Max-
TOPO (Invitrogen) and then transformed into the DH5
 
 
 
 high-
efficiency competent 
 
Escherichia coli
 
 (GIBCO BRL). Recombi-
nant colonies were selected using Zeocin (25 
 
 
 
g/ml; Invitrogen).
Plasmid DNA from seven clones was purified using QIAprep
(QIAGEN), sequenced using Big Dye Terminator Cycle Se-
quencing Kit according to the manufacturer’s protocol and ana-
lyzed on an ABI Prism Genetic Analyzer 310 (Applied Bio-
systems).
 
Expression of JAM-3 Construct in CHO Cells.
 
CHO cells
were grown in Ham’s F12 medium supplemented with 10% fetal
calf serum and 0.5% penicillin/streptomycine and were trans-
fected with JAM-3 construct by the use of Lipofectamine
(GIBCO BRL). In brief, 1 
 
 
 
g of the JAM-3 construct was mixed
with 15 
 
 
 
l lipofectamine in 200 
 
 
 
l OptiMEM and then added to
subconfluent CHO cells. After 5 h, 2 ml Ham’s F12 medium
containing 10% FCS was added and the incubation was contin-
ued for 48 h. After splitting, stable transfectants were selected
with Zeocin (final concentration 200 
 
 
 
g/ml; Invitrogen) for 2
wk and subcloned. Transfectants expressing recombinant JAM-3
were identified by flow cytometry analysis using mAb Gi11. A
positive clone was enriched by the use of MACS MicroBeads
coupled with goat anti–mouse IgG (Miltenyi Biotec).
 
Isolation of Cells from Peripheral Blood.
 
Platelets were isolated
from acid-citrate-dextrose (ACD) anticoagulated blood and
washed with Tyrode’s buffer containing prostaglandin E1 and
apyrase as described previously (27). For the isolation of white
blood cells, blood was diluted with an equal volume of PBS, lay-
ered onto Ficoll-Plaque™ Plus (Amersham Biosciences) and cen-
trifuged with 17,000 
 
g
 
, at 20 C for 35 min. Mononuclear cells
were recovered from the interface and washed twice with PBS.
Monocytes were then separated from lymphocytes as described
previously (28). Granulocytes were isolated from the red blood
cell fraction by lysis of erythrocytes with ammonium chloride.
Determination of JAM-3 Expression by Flow Cytometry. 100   l
cell suspensions were incubated with 20  l mAb Gi11 (0.02 mg/
ml) at 4 C for 30 min, washed twice, and labeled with 100  l flu-
orescein isothiocyanate-conjugated rabbit anti–mouse IgG (1:80
dilution; Dako). Cells were resuspended in 500  l PBS contain-
ing 0.5% BSA and analyzed by flow cytometry on a FACSCali-
bur™ (Becton Dickinson). Antibody binding was quantified us-
ing DAKO QIFIKIT Calibrations Beads (Dako).
Cell Lines. Myelomonocytic cells (U937) were from Ameri-
can Type Culture Collection and were cultured in RPMI-1640
containing 10% FCS. K562 cells (nontransfected, and transfected
with LFA-1 or p150.95) were provided by Dr. Y. van Kooyk
(University Medical Center, Nijmegen, Netherlands) and were
cultured in a mixture of 75% RPMI-1640 containing 10% FCS
and 25% ISCOVE’s medium supplemented with 5% FCS.
K562 cells transfected with Mac-1 were provided by Dr. M.
Smith (Celltech, Slough, UK). All culture media were from
GIBCO BRL.
Cell Adhesion Assay. Cell adhesion to JAM-3, fibrinogen
(Kabivitrum) or BSA (as control) coated plates was tested as de-
scribed previously (29). Briefly, microtiter plates were coated
with 10  g/ml JAM-3 or fibrinogen (in bicarbonate buffer, pH
9.6), respectively, and blocked with 3% BSA solution. U937
cells, which had been differentiated for 24 h in the presence of
vitamin D3 (100 nM; Biomol) and transforming growth factor- 
(2 ng/ml; R&D Systems), or K562 cells were washed in serum-
free RPMI and plated onto the precoated wells (105/well) at
37 C for 60 min in the absence or presence of inhibitors. After
the incubation period, the wells were washed and adherent cells
were fixed with methanol/acetone (1:1) at 4 C for 30 min. Ad-
herent cells were then stained with crystal violet and quantified
by measuring absorbance at 590 nm.
Fluorescence Adhesion Assay. Adhesion of neutrophils, U937
cells or K562 cells to immobilized ligands, surface-adherent plate-
lets or to CHO cells was investigated as described (30). Briefly,
nontransfected CHO or JAM-3–transfected CHO cells were
grown to confluency onto 96-well plates. Human platelets (1.5  
107/well) were added to microtiter plates precoated with 0.2%
gelatin. After 1 h at 37 C unbound platelets were removed. Fluo-
rescence labeled neutrophils (105/well), differentiated U937 cells
or K562 cells were washed twice followed by no pretreatment or
stimulation with phorbol myristate acetate (PMA; 50 ng/ml) or
the  2-integrin stimulating mAb Kim127 (10  g/ml). Cells were
washed and added to immobilized JAM-3, platelets or to CHO
cells at 37 C for 60 min in the absence or presence of inhibitors.
After washing, adhesion of neutrophils, U937, or K562 cells was
quantified as the percentage of total cells added using a fluores-
cence microplate reader (Bio-Tek). When purified JAM-3 was
used as a competitor in both adhesion assays the final concentra-
tion of NP-40 in the buffer was less than 0.005% and did not af-
fect the assay at all.
ELISA for Ligand–Receptor Interactions. A previously outlined
procedure was used (30). Briefly, maxisorp plates (Greiner) were
coated with Mac-1 or LFA-1 (5  g/ml) dissolved in 20 mM
HEPES, 150 mM NaCl, 1 mM Mn2 , pH 7.2 (HEPES buffer),
and then blocked with 3% BSA in HEPES buffer. Binding of
ICAM-1 (10  g/ml), JAM-3 (0–15  g/ml), or biotinylated fi-
brinogen (2  g/ml) to the immobilized integrin was performed
in a final volume of 50  l (HEPES buffer supplemented with
0.05% Tween-20) in the absence or presence of inhibitors. After
incubation at 22 C for 2 h and a washing step, bound JAM-3 was
detected by biotinylated mAb Gi11 and peroxidase-conjugated
streptavidin (1:2,000 dilution; Dako), bound ICAM-1 was de-
tected by appropriate mAb and peroxidase-conjugated goat anti–
mouse immunoglobulin (1:2,000 dilution; Dako). Biotinylated fi-
brinogen was detected directly with peroxidase-conjugated
streptavidin (see above). Bound antibodies or streptavidin
were quantified using 2,2 -azino-di-[3-ethylbenzthiazoline sul-
fonate(6)] as substrate (Boehringer Mannheim) in a microplate
reader (Molecular Devices) at 405 nm. Nonspecific binding to
BSA-coated wells was used as blank and was subtracted to calcu-
late specific binding.682 JAM-3 Is a Counterreceptor for Mac-1
Determination of Platelet Adhesion to Neutrophils in Whole
Blood. Whole blood adhesion experiments were performed in a
micro-couette as described (31–33). ACD anticoagulated blood
was obtained from healthy volunteers, diluted 1:1 with Tyrode
buffer and subjected to shear (20 and 2,000 s 1) for 10 min at
37 C in the presence of 10  l inhibitors. The samples were fixed
with a fixative containing methacroleine (32). Leukocyte-platelet
aggregates were determined by two color flow cytometry in
FACScan™ (Becton Dickinson) using FITC-labeled mAb against
CD41a (Beckman Coulter) and PE-labeled mAb against CD66
(Beckman Coulter).
Data Analysis and Statistical Analysis. Data analysis was per-
formed using Internet-based tools BLAST2.0 (http://www.ch.
embnet.org), CLUSTAL (http://genius.embnet.dkfz-heidelberg.
de), and SMART (http://smart.EMBL-Heidelberg.de). Statisti-
cal analysis was performed using analysis of variance (ANOVA)
and the Student’s t test; P values of  0.05 were regarded as sig-
nificant.
Results
Detection, Purification, and Molecular Identification of Platelet
Gi11 and Gi13 Antigen. To isolate the Gi11 antigen ali-
quots of 500 ml platelet lysates derived from  5   1012
outdated platelets were applied to normal mouse IgG,
mAb w6/32 and mAb Gi11 affinity columns. Approxi-
mately 1.1 mg purified Gi11-protein could be isolated
from a single affinity adsorption/desorption run. Silver
staining of the major fractions showed a band with Mr of
43 kD which reacted with mAb Gi11 as well as with mAb
Gi13 in immunoblotting under reducing conditions (Fig.
1). Both mAb recognized different epitopes on Gi11-anti-
gen as was deduced from binding competition experiments
(unpublished data).
The sequence analysis of the immunoreactive 43 kD
protein yielded 14 NH2-terminal residues (VNLKSSNRT-
PVVQEF). In addition, the amino terminal sequence of
three major internal proteolytic fragments IQDEQT-
TYVFF, SLKIWNVT, and MATLHCQESEGHPR-
PHYSWYR could be identified (Fig. 2). Alignment of the
NH2-terminal sequence and the proteolytic fragments with
the protein database of the National Center for Bio-
technology Information using BLAST 2.0 showed signifi-
cant similarity with a protein sequence derived from hu-
man fetal brain (GenBank/EMBL/DDBJ accession no.
AF356518.1) that was recently described by Arrate et al. as
JAM-3 (34). The complete nucleotide sequence of human
platelet JAM-3 cDNA derived from RACE-PCR and the
deduced amino acid sequence is shown in Fig. 2 A.
Analysis of the Platelet JAM-3 Amino Acid Sequence.
Platelet JAM-3 is encoded by a mRNA of 1740 bases that
encodes a protein of 310 amino acids with a signal se-
quence corresponding to amino acids 1–31. JAM-3 is a
type I integral membrane protein with an extracellular
amino-terminus (residues 32–310), a transmembrane do-
main (residues 245–267), and a cytoplasmic oriented car-
boxy-terminus (residues 268–310). Furthermore, the pro-
tein contains two potential N-glycosylation (Asn104, Asn192)
sites and one potential O-glycosylation site (Thr60). The
cytoplasmic tail contains three potential phosphorylation
sites (Tyr270,282, 293) and a putative phosphorylation site for
casein kinase II (Thr296) or protein kinase C (Ser281). At the
extreme carboxy-terminus, a potential binding motif for
PDZ domains is apparent. JAM-3 exhibits two regions
(amino acids 44–122 and 151–226) of high homology to
members of the immunoglobulin superfamily. Based on the
analysis using the SMART program these two regions rep-
resent C2-type immunoglobulin domains.
Alignment of Human JAM-3 with Human and Murine
JAMs. Multiple sequence alignment of human JAM-3 re-
vealed 36% identity with human JAM-2 and 32% with hu-
man JAM-1, whereas comparison with the known murine
JAM-1, -2, and –3 showed amino acid identities of 34, 86,
and 35%, respectively. Human JAM-3 is more closely re-
lated to murine JAM-2 than to murine JAM-1 or murine
JAM-3. Murine JAM-3 is related to human JAM-2 (79%
homology), whereas murine JAM-1 is related to human
JAM-1 (67% homology). The phylogenetic tree of hu-
man and murine JAMs and the alignment between human
JAM-3 and murine JAM-2 are shown in Fig. 2, B and C.
Cellular Distribution of JAM-3. To examine the expres-
sion of JAM-3 in various peripheral blood cells, the surface
expression of JAM-3 on platelets, granulocytes, monocytes,
lymphocytes, and erythrocytes isolated from healthy blood
donors was analyzed by flow cytometry using mAb Gi11
(Fig. 3). Significant JAM-3 expression was only detected
on platelets, but not on other blood cells. Quantitative de-
termination demonstrated that platelets possess 1594   303
copies (n   6) of JAM-3 on their surface. Analysis with
myeloid cell lines (K562, U937, HL-60, HEL VJ20, MEG-
01, KG1a, and Dami) indicated that JAM-3 is only ex-
pressed on megakaryocytic cell lines MEG-01, Dami, and
KG1a cells, but not on K562 and U937 cells (35). The ab-
sence of JAM-3 surface expression on U937 and K562 used
in our study is shown in Fig. 3.
JAM-3 Is a Counterreceptor for Mac-1. The described
homophilic or heterophilic interactions of JAMs responsi-
ble for cell–cell adhesion (17, 36) prompted us to investi-
gate the binding properties of human platelet JAM-3 in this
respect. Full-length JAM-3 was transfected into CHO cells
Figure 1. Purification and identification of Gi11 antigen from platelets.
Purified Gi11 antigen was subjected to 10% SDS-PAGE under reducing
conditions and was visualized by Coomasie blue staining (lane 2) in compar-
ison to indicated molecular weight standards (lane 1). Gi11-antigen was then
transferred onto nitrocellulose membrane, stained with mAb Gi11 or Gi13
(lanes 3 and 4) and visualized using streptavidin–chemiluminescence system.683 Santoso et al.
and stable transfectants were isolated and analyzed by flow
cytometry using mAb Gi11 (Fig. 4 A). Immunoblotting
analysis demonstrated that the recombinant JAM-3 re-
vealed the expected protein band with the molecular mass
of 43 kD compared with authentic platelet JAM-3 (Fig. 4
B). When the interaction of JAM-3–transfected CHO cells
to immobilized JAM-3 was tested, only very weak binding
was noted, indistinguishable from binding of nontrans-
fected cells (unpublished data).
In contrast, myelomonocytic U937 cells, which do not
express JAM-3, adhered strongly to JAM-3–coated plates.
This adhesion was abolished by an antibody against JAM-3
and a blocking mAb against  2-integrin, whereas a block-
ing mAb against  1-integrin had no effect. Moreover,
U937 cell adhesion to immobilized JAM-3 could be inhib-
ited by a blocking mAb against Mac-1 or by the Mac-1
ligand fibrinogen, whereas a blocking mAb against LFA-1
or p150.95 did not affect cell adhesion (Fig. 5 A). In addi-
tion, the Mac-1–mediated adhesion of U937 cells to fibrin-
ogen was inhibited by purified JAM-3 (Fig. 5 B). The same
pattern of interaction between JAM-3 and Mac-1 was
identified when the adhesion of U937 cells to JAM-3
transfected CHO cells was tested. The efficiency of cell-to-
cell adhesion was almost doubled in the presence of PMA,
Figure 2. JAM-3 cDNA sequence and deduced amino acid sequence.
(A) The NH2-terminal amino acid sequence and internal sequences de-
rived from amino acid sequence analysis are underlined. The transmem-
brane region is indicated by a double line. Putative N- (Asn104, Asn192)
and O-glycosylation sites (Thr60) are shown in bold. The protein kinase C
phosphorylation site at Ser281 is circled and PDZ binding motif is boxed.
The GenBank/EMBL/DDBJ accession no. for the nucleotide sequence
of the human platelet JAM-3 is AF448478. (B) Phylogenetic tree of ho-
mologous human (h) JAM-3 and murine (m) JAM-2. Phylogenetic dis-
tances obtained with the Clustal W program are indicated as values above
the branches. (C) Alignment of hJAM-3 and mJAM-2 was done using the
SMART program. Immunoglobulin C-2 domains and the transmem-
brane domain are indicated by single and double line, respectively. Cys-
teine residues are shown in bold and nonidentical amino acids are shaded
in dark. The mJAM-2 sequence is accessible from the database
(AJ300304).
Figure 3. Flow cytometry analysis of JAM-3 expression on blood cells,
U937 and K562 cell lines with mAb Gi11. The closed curves represent
the reaction with mAb Gi11, the thin lines with normal mouse IgG (neg-
ative control) and the bold lines with different mAb specific for the indi-
cated cell types: Gi9 ( 2 1 integrin; platelets), 3G8 (CD16; granulo-
cytes), MY4 (CD14; monocytes), w6/32 (HLA class I; lymphocytes), and
Gi21 (CD55; erythrocytes, K562 cell line) and K20 ( 1 integrin; U937
cell line).684 JAM-3 Is a Counterreceptor for Mac-1
a known activator of integrins, and adhesion was inhibited
by mAb against the common  2-subunit or Mac-1, but not
by mAbs against LFA-1, p150.95, or  1-integrins (Fig. 5
C). In any case, nontransfected CHO cells did not present
any appreciable adhesion. In these experiments, cell adhe-
sion was not only inhibited by the blocking Mac-1 mAb
LPM19c, but also by the mAb CBRM1/5, as the
CBRM1/5 activation-dependent epitope was expressed on
differentiated and PMA-stimulated U937 cells (unpub-
lished data). Finally, neutrophils isolated from peripheral
blood, also adhered specifically to immobilized JAM-3 in a
Mac-1–dependent manner (unpublished data).
To further define a direct interaction between JAM-3
and members of the  2-integrin family, the adhesion of
K562 erythroleukemic cells transfected either with LFA-1,
Mac-1, or p150.95 to immobilized JAM-3 was investi-
gated. Whereas nontransfected K562 cells or LFA-1 trans-
fectants did not show any significant adhesion to JAM-3
both under unstimulated or stimulated conditions (with
PMA or the stimulating antibody Kim127), K562 cells ex-
pressing Mac-1 or p150.95 adhered to immobilized JAM-3
especially in the presence of the  2-integrin stimulating an-
tibody Kim127 (Fig. 6 A). Similarly, only Mac-1– and
p150.95-transfected K562 cells adhered to JAM-3–trans-
fected CHO cells, whereas LFA-1 transfectants or non-
transfected cells did not adhere. Moreover, none of the
K562 cells interacted with nontransfected CHO cells (Fig.
6 C). Adhesion of Mac-1– or p150.95-transfected cells to
immobilized JAM-3 or JAM-3–transfected CHO cells was
inhibited by blocking mAb against Mac-1 and p150.95, re-
spectively, and also by a mAb against JAM-3 (Fig. 6, B and
D). Taken together, these data strongly indicate that JAM-3
acts as a novel counterreceptor for both  2-integrins
Figure 4. Characterization of CHO cells expressing stable JAM-3. (A)
Flow cytometry analysis of JAM-3 transfectants using mAb Gi11 (anti-
JAM3) and mAb Gi5 (anti-GPIIb/IIIa) is shown. The closed curves rep-
resent the reaction of antibodies with untransfected CHO cells. (B)
Immunoblotting analysis using mAb Gi11 of lysates from untransfected
cells (lane 1) or JAM-3 transfectants (lane 2) is presented. Figure 5. Leukocyte adhesion to JAM-3 is Mac-1 dependent. (A) The
adhesion of PMA-stimulated (50 ng/ml) U937 cells to immobilized
JAM-3 is shown in the absence ( ) or presence of blocking mAb against
the integrin  1-chain,  2-chain, LFA-1, Mac-1, p150.95, JAM-3 (each
10  g/ml), or soluble fibrinogen (FBG, 20  g/ml). (B) The adhesion of
PMA-stimulated (50 ng/ml) U937 cells to immobilized fibrinogen is
shown in the absence ( ) or presence of blocking mAbs against integrins
(each 10  g/ml) or purified JAM-3 (20  g/ml). Cell adhesion is ex-
pressed as absorbance at 590 nm. All data are mean   SD (n   3) of a
typical experiment; similar results were obtained in at least three separate
experiments. (C) U937 cell adhesion to nontransfected CHO cells (white
bars) or JAM-3–transfected CHO cells (black bars) was studied without or
with PMA (50 ng/ml) pretreatment as indicated, and in the absence ( )
or presence of blocking mAb against integrins or against JAM-3 (each 10
 g/ml). The number of adherent cells is expressed as percentage of total
added cells. All data are mean   SD (n   3) of a typical experiment; sim-
ilar results were obtained in at least three separate experiments; *: P  
0.01 compared with respective control; ns, not significant.685 Santoso et al.
Mac-1 and p150.95 and is capable of mediating hetero-
philic cell–cell interactions.
JAM-3 Directly Binds to Mac-1. As the previous obser-
vations suggested a direct molecular interaction between
the  2-integrin Mac-1 and JAM-3, the direct binding of
JAM-3 to immobilized purified Mac-1 in comparison to
LFA-1 was analyzed. JAM-3 directly bound to Mac-1, and
this binding was similar in its extent to the binding of
ICAM-1 or fibrinogen, which both are known ligands for
Mac-1 (Fig. 7 A). Moreover, binding of JAM-3 to Mac-1
presented a saturable dose-dependency (Fig. 7 B) and was
inhibited by a mAb against Mac-1 and a mAb against JAM-3
(Fig. 7 C). In contrast, no specific binding of JAM-3 to im-
mobilized LFA-1 was identified, whereas the expected
binding of ICAM-1 to LFA-1 was apparent (Fig. 7 A). As
fibrinogen was shown to inhibit the Mac-1–dependent ad-
hesion of U937 cells to immobilized JAM-3 (see Fig. 5 A),
the possibility that the two Mac-1 ligands, fibrinogen, and
JAM-3, may compete for each other was tested. Fibrinogen
inhibited the binding of JAM-3 to immobilized Mac-1,
and vice versa, JAM-3 blocked the interaction between fi-
brinogen and Mac-1, indicative for overlapping binding
sites of both ligands on Mac-1 (Fig. 7 C). This observation
was further strengthened by demonstrating a direct interac-
tion between JAM-3 and the purified I-domain of Mac-1
(unpublished data), which also constitutes the major bind-
ing site for fibrinogen.
JAM-3 Facilitates Platelet–Leukocyte Interactions. In a re-
cent report, Simon et al. (8) demonstrated that platelet
GPIb  serves as a potential counter-receptor for leukocyte
Mac-1. However, the presence of additional Mac-1 ligands
on the surface of platelets was not ruled out. To establish
that JAM-3 can facilitate the interaction between platelets
and leukocytes, the adhesion of neutrophils isolated from
healthy volunteers or U937 cells to surface-adherent plate-
lets was analyzed. PMA- or fMLP-stimulated neutrophil
adhesion to surface-adherent platelets was abolished in the
presence of a mAb against Mac-1 but not mAb against
Figure 6. Characterization of the adhesion of K562 cells to JAM-3. (A) Adhesion of untransfected K562 cells (nt), or K562 cells transfected with
LFA-1-, Mac-1-, or p150.95 to immobilized JAM-3 was studied in the absence (white bars) or presence of PMA (50 ng/ml; gray bars) or of the  2-inte-
grin stimulating mAb Kim127 (10  g/ml; black bars). (B) Adhesion of Mac-1- or p150.95-transfectant to immobilized JAM-3 after stimulation with mAb
Kim127 in the absence (white bars) or presence of mAb against Mac-1 (dark gray bar), mAb against p150.95 (light gray bar), or mAb against JAM-3 (black
bars; each 10  g/ml). (C) Adhesion of K562 cells (nt), of LFA-1-, Mac-1-, or p150.95-transfectant to CHO cells or JAM-3–transfected CHO cells was
studied without stimulation (open bars) or after stimulation with PMA (gray bars) or with mAb Kim127 (black bars). (D) Adhesion of Mac-1- or p150.95-
transfectant to JAM-3–transfected CHO cells was studied in the absence ( ) or presence of PMA or mAb Kim127 without (white bars) or with mAb
against Mac-1 (dark gray bars), mAb against p150.95 (light gray bars) or mAb against JAM-3 (black bars; each 10  g/ml). The number of adherent
cells is expressed as percent of total added cells. All data are mean   SD (n   3) of a typical experiment; similar results were observed in at least three
separate experiments.686 JAM-3 Is a Counterreceptor for Mac-1
ICAM-2 had no effect on the neutrophil–platelet inter-
action (unpublished data). Similar results were obtained
when adhesion of U937 cells to platelets was examined
(unpublished data).
To further define the contribution of JAM-3 in mediat-
ing platelet–leukocyte interactions, the binding of neutro-
phils or U937 cells to surface-adherent platelets from a pa-
tient with Bernard-Soulier-Syndrome (BSS) was assessed.
The particular patient has a homozygous Asn45Ser muta-
tion in the GPIX gene leading to only 20% GPIb/IX sur-
face expression compared with normal subjects (unpub-
lished data). Adhesion of neutrophils to BSS-platelets was
significantly reduced as compared with normal platelets
(Fig. 8 B). In this case the inhibitory capacity of mAb
against GPIb  was hardly discernible, whereas the blocking
mAb against JAM-3 abolished the Mac-1–dependent adhe-
sion of neutrophils. Also, purified JAM-3 blocked the neu-
trophil interaction with BSS-platelets. Similar results were
obtained with U937 cells (unpublished data). Taken to-
gether, these data indicate that JAM-3, by binding to Mac-1,
facilitates the heterotypic interaction between leukocytes
and platelets. Thus, JAM-3 and GPIb  together serve as
the major Mac-1 counterreceptors on the platelet surface.
Relevance of JAM-3 in Platelet–Leukocyte Aggregates in
Whole Blood. To further substantiate the physiological
relevance of the interaction between JAM-3 and Mac-1
the ex vivo detection of platelet–neutrophil aggregates
from whole blood was performed in a micro-couette both
under conditions of low and high shear. The formation of
these aggregates was almost completely abolished in the
presence of antibody against P-selectin. Soluble glycocali-
cin reduced the aggregate formation under both conditions
of low and high shear rate, whereas purified JAM-3 pro-
vided a significant inhibition only under conditions of low
shear (Fig. 9).
Discussion
Leukocyte recruitment to the site of inflammation or in-
fection depends on the interactions of these mobile cells
with the vessel wall, reactions which are largely controlled
by the degree and duration of adhesive contacts of the in-
volved cell types. In particular, leukocytes interact with the
intact endothelium or with deposited platelets and fibrin at
sites of vascular injury after denudation of the endothelial
cell lining. Upon certain pathological conditions leukocytes
and platelets colocalize in the vessel wall (4–6, 37). A se-
quential adhesion model of leukocyte attachment to and
transmigration across surface-adherent platelets has been
proposed, including P-selectin-mediated initial rolling (7)
and the subsequent Mac-1–dependent firm adhesion and
transplatelet migration (38–40). However, the potential
platelet counterreceptors for Mac-1 are only partially iden-
tified. In this study, a third member of the family of junc-
tional adhesion molecules, JAM-3, was characterized as a
novel counterreceptor on platelets for leukocyte Mac-1.
Together with GPIb , JAM-3 serves as the major hetero-
Figure 7. Interaction between purified JAM-3 and Mac-1 proteins. (A)
The binding of ICAM-1, fibrinogen (FBG), or JAM-3 to immobilized
Mac-1 (black bars) and the binding of JAM-3 or ICAM-1 to immobilized
LFA-1 (white bars) was studied. (B) Dose-dependent specific binding of
JAM-3 to immobilized Mac-1 is shown. (C) The binding of JAM-3
(white bars) to immobilized Mac-1 was analyzed in the absence ( ) or
presence of fibrinogen (FBG, 20  g/ml), mAb against Mac-1 or mAb
against JAM-3 (each 10  g/ml). The binding of fibrinogen (black bars) to
immobilized Mac-1 was studied in the absence ( ) or presence of puri-
fied JAM-3 (20  g/ml) or of mAb against Mac-1 (10  g/ml). Specific
binding is expressed as absorbance at 405 nm. Data are mean   SD (n  
3) of a typical experiment; similar results were observed in at least three
separate experiments.
LFA-1 or p150.95 (Fig. 8 A and Table I). Individual anti-
bodies against JAM-3, mAb Gi13, or rabbit anti–JAM-3,
or anti-GPIb  antibody partially reduced adhesion of neu-
trophils to platelets, and the combination of both antibod-
ies completely abolished binding of neutrophils to platelets,
suggesting that JAM-3 and GPIb  on the platelet surface
together serve as the predominant counterreceptors for
Mac-1. Moreover, the addition of purified JAM-3 could
completely inhibit binding of neutrophils to surface-adher-
ent platelets (Fig. 8 A and Table I), an effect that appeared
to be comparable to the inhibitory capacity of soluble
glycocalicin in the same system. Blocking other poten-
tial  Mac-1 ligands such as  IIb 3-bound fibrinogen or687 Santoso et al.
typic adhesion receptor responsible for cell-to-cell adhesion
between platelets and leukocytes.
In particular, two mAb Gi11 and Gi13 had been raised
against a 43-kD glycoprotein on human platelets and these
tools allowed the identification of a full-length cDNA en-
coding a 279-amino acid mature protein. This type I inte-
gral membrane glycoprotein reveals two domains with in-
trachain disulfide bonds at the extracellular region, typical
for Ig-loops of the immunoglobulin superfamily and is
identical with the very recently described human JAM-3
(34). Multiple sequence alignments of the protein revealed
the highest amino acid identity (86%) with murine JAM-2
(41), whereas the homology between murine JAM-3 and
human JAM-2 was 79%. Thus, murine JAM-2 represents
the mouse counterpart of human JAM-3 and vice versa,
murine JAM-3 is the mouse counterpart of human JAM-2.
The analysis of different peripheral blood cell populations
and cell lines indicated that JAM-3 is exclusively expressed
on platelets or megakaryoblastic cell lines.
A possible engagement of JAM-3 in homophilic cellular
interactions could hardly be identified, as opposed to the
properties of two previously described members of the
JAM family (17, 23). However, the following features of
JAM-3 are consistent with a specific heterophilic interac-
Figure 8. JAM-3 mediates plate-
let–leukocyte adhesive interactions.
(A) PMA-stimulated adhesion of hu-
man neutrophils to surface-adherent
platelets was studied in the absence
( ) or presence of mAb against
Mac-1, LFA-1, JAM-3, or GPIb  as
well as a mixture of mAbs against
JAM-3 and GPIb  (each 10  g/ml)
or in the presence of purified JAM-3
or soluble glycocalicin (GPIb ; each
10   g/ml), respectively. Data are
mean   SD (n   3) of a typical ex-
periment; similar results were ob-
served in at least three separate ex-
periments. (B) Adhesion of human
neutrophils to surface-adherent
platelets from a patient with Ber-
nard-Soulier-Syndrome was studied
in the absence ( ) or presence of
mAb against Mac-1, GPIb , or
JAM-3 (10  g/ml), or of purified
JAM-3 (10  g/ml). The number of adherent cells is expressed as percent of total added cells. Data are mean   SD (n   3) of a typical experiment; similar
results were observed in 2 separate experiments; *: P   0.01 compared with control; ns, not significant.
Table I. JAM-3 Mediates Platelet–Leukocyte Interactions
Additives Cell adhesion (% adherent cells)
None 53.2   1.8
Anti–Mac-1 5.2   1.2a
Anti-p150.95 48.4   2.3
Anti-JAM-3 24.9   2.7a
Anti-GPIb  27.1   1.9a
Anti–JEM-3   anti-GPIb  5.8   0.9a
JAM-3 4.8   0.9a
GPIb  8.2   1.7a
FMLP-stimulated adhesion of human neutrophils to surface-adherent
platelets was studied in the absence ( ) or presence of mAb against Mac-1,
p150.95, JAM-3, or GPIb  as well as a mixture of mAbs against JAM-3
and GPIb  (each 10  g/ml) or in the presence of purified JAM-3 or
soluble glycocalicin (GPIb ; each 10  g/ml), respectively. The number
of adherent cells is expressed as percent of total added cells. Data are
mean     SD (n    3) of a typical experiment; similar results were
observed in at least three separate experiments.
aP   0.01 as compared to control.
Figure 9. Role of JAM-3 in platelet–neutrophil aggregate formation in
whole blood. The platelet–neutrophil adhesion in whole blood stimu-
lated with the stable thromboxane A2 mimetic U46619 (5  M) is shown
in the absence or presence of purified JAM-3 (20  g/ml), soluble glyco-
calicin (20  g/ml), or Fab-fragments of blocking mAb GA6* against
P-selectin (PS; 10  g/ml). Adhesion experiments were performed in a
micro-couette at low (20 s 1) and high (2,000 s 1) shear rates. The data
represent mean   SD of four independent experiments.688 JAM-3 Is a Counterreceptor for Mac-1
tion with leukocyte  2-integrin Mac-1: (a) Myelomono-
cytic U937 cells adhered to immobilized JAM-3 or JAM-3
transfected cells and this interaction was attributed to
Mac-1. (b) Analyzing adhesion of K562 cells transfected
with different  2-integrins to either immobilized JAM-3 or
JAM-3-transfected cells further established that JAM-3 in-
teracts with Mac-1 but not with LFA-1. K562 cells bearing
a third  2-integrin, p150.95, also interacted with JAM-3,
which is not surprising as p150.95 and Mac-1 share many
similarities in ligand binding (42). Although U937 cells and
neutrophils express p150.95 integrin, the adhesion of U937
cells to immobilized JAM-3 (Fig. 5), the adhesion of neu-
trophils to purified JAM-3 (unpublished data), or the adhe-
sion of neutrophils to surface-adherent platelets (Table I)
was not affected by a blocking mAb against p150.95. Simi-
larly, anti-p150.95 did not impair adhesion of U937 cells
to fibrinogen (Fig. 5). These observations indicate that
p150.95 is not sufficient to mediate adhesion to JAM-3
when coexpressed with Mac-1. Thus, Mac-1 serves as the
predominant counter-receptor of JAM-3. (c) In a purified
system, a direct binding between JAM-3 and Mac-1 was
observed. JAM-3 was particularly found to recognize the
I-domain of Mac-1 (unpublished data) and JAM-3 and fi-
brinogen competed with each other for binding to Mac-1,
suggesting overlapping binding sites on the  2-integrin.
Conversely, the exact binding epitope(s) for Mac-1 on
JAM-3 remain to be identified. (d) A major consequence
for JAM-3 binding to Mac-1 is a firm platelet–leukocyte
interaction. In this respect, antibodies to both JAM-3 and
GPIb , each partially inhibited the interaction of human
neutrophils with surface-adherent platelets, whereas a com-
bination of both antibodies totally abolished the cell–cell
interaction. In addition, either purified JAM-3 or GPIb 
alone almost completely inhibited the platelet-leukocyte
interaction, probably because each ligand may block bind-
ing sites on Mac-1 for both JAM-3 and GPIb . Further-
more, neutrophil interaction with platelets derived from a
BSS-patient was markedly reduced, compared with normal
platelets, and interestingly, neutrophil adhesion to BSS-
platelets was almost completely blocked by the antibody
against JAM-3. Thus, under our experimental conditions,
JAM-3 and GPIb  are the major mediators of neutrophil-
platelet adhesive contacts. (e) The physiological relevance
of our findings was substantiated by identifying a role for
JAM-3 in mediating platelet–leukocyte aggregates in whole
blood. Whereas soluble glycocalicin blocked aggregate for-
mation under both low and high shear rate, purified JAM-3
was effective only under low shear rate. Hence, JAM-3
mediates adhesion of neutrophils to platelets under low
shear conditions; i.e., it might strengthen the neutrophil-
platelet interaction already mediated by other Mac-1
ligands on platelets. However, a potential contribution of
JAM-3 in the accumulation of neutrophils to surface-
adherent platelets under physiological flow conditions can-
not be excluded from the data presented here.
Although we found no participation of other adhesion–
receptor systems in firm adhesion of neutrophils to plate-
lets, the possibility of additional Mac-1–dependent and
–independent binding sites on platelets cannot be ruled
out. Other potential Mac-1 ligands present on the platelet
membrane include fibrinogen (bound to GPIIb-IIIa; refer-
ence 10), ICAM-2 (43), high molecular weight kininogen
(30, 44), or glycosaminoglycans (45). In particular, the
functional relevance of fibrinogen and ICAM-2 as Mac-1
counterreceptors appears to increase with higher shear
(46). Further detailed functional analysis of the contribu-
tion of each platelet associated Mac-1 ligand in platelet/
neutrophil interactions under different shear conditions
will provide clarification in this respect. Interactions con-
tributing to Mac-1–independent leukocyte–platelet aggre-
gate formation include thrombospondin bridging between
GPIV receptors on platelets and monocytes (47) or binding
of P-selectin on activated platelets to leukocyte PSGL-1
(48, 49).
In addition to mediating the accumulation of leukocytes
at sites of platelet deposition within regions of the injured
vasculature, the juxtacrine interaction between neutrophils
and platelets can induce upregulation of neutrophil adhe-
sion molecules (50) or promote integrin activation (39),
chemokine synthesis (51, 52), and induction of the respira-
tory burst (50). Interestingly, both neutrophil–platelet and
monocyte–platelet aggregates have been identified in the
peripheral blood of patients with coronary artery disease
and may be markers of disease activity (50, 53). Thus, the
possibility that the described interaction between JAM-3
and Mac-1 contributes to such processes is intriguing and is
currently under investigation.
Recently, evidence is accumulating that JAM family
members possess important features for cellular communi-
cations between endothelium and leukocytes during the
inflammatory process. For example, JAM-1 was shown to
facilitate the transmigration of neutrophils and monocytes
across the vessel wall (12, 13, 36). JAM-1 is also proposed
to modulate paracellular permeability (14, 20), as it associ-
ates with the tight junction components ZO-1 and AF-6
via their PDZ domains (54, 55). As the PDZ binding motif
is conserved in JAM-3, future investigations will focus on a
putative role for JAM-3 in endothelial barrier function. In
contrast to JAM-1, which has already been implicated in
single patients with immune thrombocytopenia, JAM-3
does not represent a major target for platelet antibodies
as almost 1,000 patients with various forms of immune
thrombocytopenia were negative for JAM-3–reactive anti-
bodies (unpublished data).
Due to the fact that JAM-1 has been shown to undergo
homophilic binding interactions, the propensity of dimer-
ization (or multimerization) has been suggested. However,
a recent report points to the role of JAM-1 also in hetero-
philic interactions by demonstrating its binding to the  2-
integrin LFA-1 (36). The observation that JAM-1 and
JAM-3 can independently function as counterreceptors for
the  2-integrins LFA-1 and Mac-1, respectively, provides a
completely new perspective in understanding alternative
processes responsible for the (patho-)physiology of inflam-
matory cell recruitment.
Taken together, this study reports the characterization of689 Santoso et al.
a novel member of the JAM family, JAM-3 from human
platelets, which constitutes a specific counterreceptor for
leukocyte Mac-1 and thereby contributes as a major adhe-
sion molecule in the platelet–leukocyte interaction. Future
studies will also aim to further characterize the molecular
anatomy of the JAM-3/Mac-1 interaction and to identify
novel strategies that could disrupt platelet–leukocyte com-
plexes in order to device therapeutic interventions in
atherothrombosis and postangioplasty restenosis.
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